{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:26:38Z","timestamp":1786973198325,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58205-7","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:44:51Z","timestamp":1781639091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between obesity and outcomes of first-line CDK4\/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-3936","authenticated-orcid":false,"given":"Murat","family":"G\u00fcnalt\u0131l\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Guliyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Birsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7erme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vali","family":"Aliyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclin Alkan","family":"\u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Kaan","family":"G\u00fcren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"\u00d6zge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lkay","family":"G\u00fclt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeysa","family":"\u00c7olak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Vedat","family":"Bayo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Hande","family":"Turna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebi Serkan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"3","key":"58205_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F -Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"58205_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN -Giaquinto","year":"2022","unstructured":"Giaquinto, A. N. et al. Breast Cancer Statistics, 2022. CA Cancer J. Clin. 72 (6), 524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"58205_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcancer.2023.09.003","volume":"96","author":"D -Nahmias-Blank","year":"2023","unstructured":"Nahmias-Blank, D. et al. Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives. Semin Cancer Biol. 96, 26\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2023.09.003 (2023).","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"58205_CR4","doi-asserted-by":"publisher","first-page":"23690","DOI":"10.1038\/s41598-024-74746-1","volume":"14","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis. Sci. Rep. 14 (1), 23690. https:\/\/doi.org\/10.1038\/s41598-024-74746-1 (2024). Published 2024 Oct 10.","journal-title":"Sci. Rep."},{"key":"58205_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2017.10.007","volume":"87","author":"E -Biganzoli","year":"2017","unstructured":"Biganzoli, E. et al. Recurrence dynamics of breast cancer according to baseline body mass index. Eur. J. Cancer. 87, 10\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.007 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"58205_CR6","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/s41416-024-02833-1","volume":"131","author":"SR -Javed","year":"2024","unstructured":"Javed, S. R., Skolariki, A., Zameer, M. Z. & Lord, S. R. Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer. Br. J. Cancer. 131 (11), 1724\u20131736. https:\/\/doi.org\/10.1038\/s41416-024-02833-1 (2024).","journal-title":"Br. J. Cancer"},{"issue":"23","key":"58205_CR7","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1002\/cncr.27527","volume":"118","author":"JA -Sparano","year":"2012","unstructured":"Sparano, J. A. et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118 (23), 5937\u20135946. https:\/\/doi.org\/10.1002\/cncr.27527 (2012).","journal-title":"Cancer"},{"issue":"10","key":"58205_CR8","doi-asserted-by":"publisher","first-page":"e2337780","DOI":"10.1001\/jamanetworkopen.2023.37780","volume":"6","author":"S -Harborg","year":"2023","unstructured":"Harborg, S. et al. Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors. JAMA Netw. Open. 6 (10), e2337780. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.37780 (2023). Published 2023 Oct 2.","journal-title":"JAMA Netw. Open."},{"issue":"6","key":"58205_CR9","doi-asserted-by":"publisher","first-page":"pkad092","DOI":"10.1093\/jncics\/pkad092","volume":"7","author":"SWM -Lammers","year":"2023","unstructured":"Lammers, S. W. M. et al. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectr. 7 (6), pkad092. https:\/\/doi.org\/10.1093\/jncics\/pkad092 (2023).","journal-title":"JNCI Cancer Spectr."},{"key":"58205_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.breast.2020.11.014","volume":"55","author":"K -Saleh","year":"2021","unstructured":"Saleh, K. et al. Impact of body mass index on overall survival in patients with metastatic breast cancer: results from the French ESME-MBC cohort. Breast 55, 16\u201324. https:\/\/doi.org\/10.1016\/j.breast.2020.11.014 (2021).","journal-title":"Breast"},{"issue":"4","key":"58205_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/cam4.634","volume":"5","author":"NM -Tsang","year":"2016","unstructured":"Tsang, N. M. et al. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 5 (4), 665\u2013675. https:\/\/doi.org\/10.1002\/cam4.634 (2016).","journal-title":"Cancer Med."},{"issue":"9","key":"58205_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","volume":"18","author":"H -Lennon","year":"2016","unstructured":"Lennon, H., Sperrin, M., Badrick, E. & Renehan, A. G. The Obesity Paradox in Cancer: a Review. Curr. Oncol. Rep. 18 (9), 56. https:\/\/doi.org\/10.1007\/s11912-016-0539-4 (2016).","journal-title":"Curr. Oncol. Rep."},{"issue":"10","key":"58205_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN -Hortobagyi","year":"2022","unstructured":"Hortobagyi, G. N. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N. Engl. J. Med. 386 (10), 942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663 (2022).","journal-title":"N Engl. J. Med."},{"issue":"9","key":"58205_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ -Slamon","year":"2024","unstructured":"Slamon, D. J. et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J. Clin. Oncol. 42 (9), 994\u20131000. https:\/\/doi.org\/10.1200\/JCO.23.00137 (2024).","journal-title":"J. Clin. Oncol."},{"key":"58205_CR15","doi-asserted-by":"publisher","unstructured":"Stanciu, I. M., Parosanu, A. I. & Nitipir, C. An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast cancer-a systematic review of randomized phase II and III clinical trials. Biomolecules. 13 (9), 1422. https:\/\/doi.org\/10.3390\/biom13091422 (2023).","DOI":"10.3390\/biom13091422"},{"issue":"1","key":"58205_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1186\/s12885-025-14223-8","volume":"25","author":"B -Yang","year":"2025","unstructured":"Yang, B. et al. Safety and quality of life of CDK4\/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China. BMC Cancer. 25 (1), 951. https:\/\/doi.org\/10.1186\/s12885-025-14223-8 (2025). Published 2025 May 27.","journal-title":"BMC Cancer"},{"issue":"4","key":"58205_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/cancers17040693","volume":"17","author":"M -Guliyev","year":"2025","unstructured":"Guliyev, M. et al. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4\/6 Inhibitors. Cancers (Basel). 17 (4), 693. https:\/\/doi.org\/10.3390\/cancers17040693 (2025).","journal-title":"Cancers (Basel)"},{"issue":"5","key":"58205_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-024-04641-z","volume":"93","author":"KB -Y\u00fccel","year":"2024","unstructured":"Y\u00fccel, K. B. et al. Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4\/6 inhibitors. Cancer Chemother. Pharmacol. 93 (5), 497\u2013507. https:\/\/doi.org\/10.1007\/s00280-024-04641-z (2024).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"58205_CR19","doi-asserted-by":"publisher","first-page":"114906","DOI":"10.1016\/j.biopha.2023.114906","volume":"164","author":"R -Roncato","year":"2023","unstructured":"Roncato, R. et al. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. Biomed. Pharmacother. 164, 114906. https:\/\/doi.org\/10.1016\/j.biopha.2023.114906 (2023).","journal-title":"Biomed. Pharmacother"},{"issue":"2","key":"58205_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10549-023-07108-6","volume":"203","author":"SWM -Lammers","year":"2024","unstructured":"Lammers, S. W. M. et al. The prognostic impact of BMI in patients with HR+\/HER2- advanced breast cancer: a study of the SONABRE registry. Breast Cancer Res. Treat. 203 (2), 339\u2013349. https:\/\/doi.org\/10.1007\/s10549-023-07108-6 (2024).","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"58205_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jnci\/djaa116","volume":"113","author":"MA -Franzoi","year":"2021","unstructured":"Franzoi, M. A. et al. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. J. Natl. Cancer Inst. 113 (4), 462\u2013470. https:\/\/doi.org\/10.1093\/jnci\/djaa116 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"58205_CR22","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F -Cardoso","year":"2024","unstructured":"Cardoso, F. et al. 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76, 103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756 (2024). 6.","journal-title":"Breast"},{"key":"58205_CR23","first-page":"1","volume":"894","author":"-World Health Organization","year":"2000","unstructured":"World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. World Health Organ. Tech. Rep. Ser. 894, 1\u2013253 (2000).","journal-title":"World Health Organ. Tech. Rep. Ser."},{"issue":"32","key":"58205_CR24","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.21.02017","volume":"40","author":"A -Gilbert","year":"2022","unstructured":"Gilbert, A. et al. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events. J. Clin. Oncol. 40 (32), 3770\u20133780. https:\/\/doi.org\/10.1200\/JCO.21.02017 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"58205_CR25","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM -Chan","year":"2014","unstructured":"Chan, D. S. M. et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25 (10), 1901\u20131914. https:\/\/doi.org\/10.1093\/annonc\/mdu042 (2014).","journal-title":"Ann. Oncol."},{"issue":"2","key":"58205_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12094-024-03563-9","volume":"27","author":"YH -Kong","year":"2025","unstructured":"Kong, Y. H. et al. The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis. Clin. Transl Oncol. 27 (2), 403\u2013416. https:\/\/doi.org\/10.1007\/s12094-024-03563-9 (2025).","journal-title":"Clin. Transl Oncol."},{"issue":"3","key":"58205_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","volume":"123","author":"M -Protani","year":"2010","unstructured":"Protani, M., Coory, M. & Martin, J. H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res. Treat. 123 (3), 627\u2013635. https:\/\/doi.org\/10.1007\/s10549-010-0990-0 (2010).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"58205_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","volume":"29","author":"M -Ewertz","year":"2011","unstructured":"Ewertz, M. et al. Effect of obesity on prognosis after early-stage breast cancer. J. Clin. Oncol. 29 (1), 25\u201331. https:\/\/doi.org\/10.1200\/JCO.2010.29.7614 (2011).","journal-title":"J. Clin. Oncol."},{"key":"58205_CR29","doi-asserted-by":"publisher","unstructured":"Jung, Y. B., Ahn, H. K., Shin, H. Y., Hong, J. H. & Rim, C. H. The impact of obesity on treatment outcomes in patients with hormone receptor-positive HER2-negative metastatic breast cancer receiving CDK 4\/6 inhibitors. Cancer Res. Treat. 15 https:\/\/doi.org\/10.4143\/crt.2025.110 (2025).","DOI":"10.4143\/crt.2025.110"},{"issue":"38","key":"58205_CR30","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1080\/14796694.2024.2402212","volume":"20","author":"D -\u00c7a\u011flayan","year":"2024","unstructured":"\u00c7a\u011flayan, D. et al. The impact of body mass index on the progression-free survival of CDK 4\/6 inhibitors in metastatic breast cancer patients. Future Oncol. 20 (38), 3099\u20133105. https:\/\/doi.org\/10.1080\/14796694.2024.2402212 (2024).","journal-title":"Future Oncol."},{"key":"58205_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.clnesp.2025.04.019","volume":"67","author":"X -Lin","year":"2025","unstructured":"Lin, X. et al. Body mass index and clinical outcomes in breast cancer patients undergoing endocrine therapy: A meta-analysis and Mendelian randomization study. Clin. Nutr. ESPEN. 67, 721\u2013730. https:\/\/doi.org\/10.1016\/j.clnesp.2025.04.019 (2025).","journal-title":"Clin. Nutr. ESPEN"},{"key":"58205_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-019-0121-y","volume":"5","author":"A -Marra","year":"2019","unstructured":"Marra, A. & Curigliano, G. Are all cyclin-dependent kinases 4\/6 inhibitors created equal? NPJ Breast Cancer. 5, 27. https:\/\/doi.org\/10.1038\/s41523-019-0121-y (2019).","journal-title":"NPJ Breast Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58205-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:49:05Z","timestamp":1786970945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58205-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58205"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58205-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Istanbul University-Cerrahpa\u015fa, Cerrahpa\u015fa Medical Faculty, Turkey (approval date: 12 December 2023; approval number: E-83045809-604.01.01-860595).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for participation is not required as per local legislation, as confirmed by the Ethics Committee of Istanbul University-Cerrahpa\u015fa, Cerrahpa\u015fa Medical Faculty, due to the retrospective design of the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25707"}}